Advaxis Launches MINE(TM) Collaboration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Advaxis (ADXS) Launches MINE Collaboration with MSK Cancer Center
October 27, 2015 9:04 AM EDTAdvaxis (NASDAQ: ADXS) announced the launch of a research collaboration with Memorial Sloan Kettering Cancer Center (MSK), a premier cancer center committed to patient care and innovative research, to evaluate the immunologic and anti-tumor activity of patient tumor-specific, neoepitope-based immunotherapy.
The goal of the collaboration, titled MINE (My Immunotherapy Neo-Epitopes), is to use Advaxiss Lm Technology to develop neo-epitope immunotherapies based on an individual patients tumor (ADXS-NEO). MINE will first focus on a preclinical study of Advaxiss new construct approach to evaluate the immunologic... More
